ONWARD Medical N.V.

ONWARD Medical N.V. is a neurotechnology company dedicated to pioneering therapies that aim to restore movement, function, and independence for individuals living with spinal cord injuries (SCI) and other movement disabilities. The company was formed in 2015 by neuroscience researchers and is headquartered in Eindhoven, the Netherlands, with a Science and Engineering Center in Lausanne, Switzerland, and a growing US team based in Boston, Massachusetts.

ONWARD's core offerings revolve around its proprietary ARC Therapy, which encompasses two primary platforms: the non-invasive ARC-EX® System and the investigational implantable ARC-IM® System. The ARC-EX System, which has received FDA clearance in the US and CE Mark certification in Europe, delivers transcutaneous electrical spinal cord stimulation to improve hand sensation and strength in individuals with incomplete spinal cord injury (C2-C8) and is also cleared for home use in the US. The ARC-IM System is an investigational implantable device designed to address critical unmet needs, such as blood pressure instability after SCI, and can be paired with an investigational brain-computer interface (BCI) platform, ARC-BCI, for thought-driven movement restoration.

As a publicly traded entity on Euronext (ONWD) and with US ADRs on OTCQX (ONWRY), ONWARD Medical has demonstrated significant recent activity. In April 2026, the company successfully raised over EUR 40 million through a capital increase. Dave Marver serves as the Chief Executive Officer, having been appointed in July 2020, and Ali Kiboro joined as Chief Financial Officer in January 2026. The company reported full-year 2025 results highlighting strong US commercial performance, including EUR 5.4 million in revenue and the sale of 117 ARC-EX Systems, alongside key pipeline milestones. ONWARD has also been recognized with 10 Breakthrough Device Designations from the FDA, underscoring its innovative approach in neurotechnology.